PROSPECTUS
HAWAIIAN HOLDINGS, INC.
Warrants to Purchase 1,134,685 Shares of Common Stock
1,134,685 Shares of Common Stock
Offered by the Selling Securityholder
The selling securityholder identified herein, or any other selling securityholder identified in supplements to this prospectus, may from time to time offer or sell (i) (a) a warrant to purchase 117,335 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on April 22, 2020, (b) a warrant to purchase 148,457 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on May 29, 2020, (c) a warrant to purchase 148,457 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on June 30, 2020, (d) a warrant to purchase 74,228 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on July 30, 2020 and (e) a warrant to purchase 21,487 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on September 30, 2020 ((a)-(e), collectively, the “PSP Warrants”), (ii) a warrant to purchase 380,711 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on September 25, 2020 (the “ERP Warrant”), (iii) (a) a warrant to purchase 113,940 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on March 5, 2021 and (b) a warrant to purchase 42,400 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on April 23, 2021 ((a) and (b), collectively, the “PSP Extension Warrants”), (iv) a warrant to purchase 87,670 shares of our common stock, par value $0.01 per share, issued to the selling securityholder on June 3, 2021 (the “PSP3 Warrant” and, together with the PSP Warrants, the ERP Warrant and the PSP Extension Warrants, the “Warrants”), and (v) up to 1,134,685 shares of our common stock issuable upon exercise of the Warrants (the “Warrant Shares”). The Warrants and the Warrant Shares are referred to collectively in this prospectus as the “Securities.” The Warrants were acquired by the selling securityholder in connection with our participation in the Payroll Support Program (“PSP”) and the Economic Relief Program (“ERP”) under the Coronavirus Aid, Relief and Economic Security Act, the Payroll Support Program Extension (the “PSP Extension”) under Subtitle A of Title IV of Division N of the Consolidated Appropriations Act, 2021 and the Payroll Support Program 3 (the “PSP3”) under Section 7301 of the American Rescue Plan Act of 2021, and are more fully described under the heading “Description of Warrants.” To the extent that the selling securityholder resells any Securities, the selling securityholder may be required to provide you with this prospectus and a prospectus supplement identifying and containing specific information about the selling securityholder and the amount and terms of the Securities being offered. You should read this prospectus and any applicable prospectus supplement before you invest. We will not receive any proceeds from the resale of any Securities by the selling securityholder, but we have agreed to pay certain registration and offering expenses. Upon exercise of any of the Warrants, however, we will receive the exercise price of the Warrant exercised for the shares issued upon such exercise. The selling securityholder will be responsible for all underwriting fees, discounts and commissions, if any, in connection with the resale of the Securities offered by this prospectus or any related prospectus supplement.
The selling securityholder may offer and sell the Securities to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods on a continuous or delayed basis. If any underwriters, dealers or agents are involved in the sale of the Securities by the selling securityholder, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. The price to the public of those Securities and the net proceeds the selling securityholder expects to receive from the sale of such Securities will also be set forth in a prospectus supplement. See the sections of this prospectus titled “About this Prospectus” and “Plan of Distribution” for more information.
We are registering the resale of the Securities by the selling securityholder in connection with the selling securityholder’s registration rights pursuant to that certain Warrant Agreement, dated as of April 22, 2020, by and between us and the United States Department of the Treasury (the “PSP Warrant Agreement”), that certain Warrant Agreement, dated as of September 25, 2020, by and between us and the United States Department of the Treasury (the “ERP Warrant Agreement”), that certain Warrant Agreement, dated as of January 15, 2021, by and between us and the United States Department of the Treasury (the “PSP Extension Warrant Agreement”), and that certain Warrant Agreement, dated as of April 23, 2021, by and between us and the United States Department of the Treasury (the “PSP3 Warrant Agreement” and, together with the PSP Warrant Agreement, the ERP Warrant Agreement and the PSP Extension Warrant Agreement, the “Warrant Agreements”), but the registration of the Securities does not necessarily mean that any of the Securities will be offered or sold by the selling securityholder pursuant to this prospectus or at all.
This prospectus describes the general manner in which the Securities may be offered and sold by the selling securityholder. Any prospectus supplement or free writing prospectus may add, update, or change information contained in this prospectus. You should read this prospectus, any prospectus supplement and any free writing prospectus, together with the documents incorporated by reference herein and therein, before you make an investment decision.
Our common stock is listed on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “HA.” On February 14, 2023, the closing price of our common stock was $10.94. There is no established trading market for the Warrants and we do not expect a market to develop. In addition, we do not intend to list the Warrants on any securities exchange or automated quotation system.
INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. SEE “RISK FACTORS ” BEGINNING ON PAGE 4 OF THIS PROSPECTUS AND IN ANY SIMILAR SECTION CONTAINED IN OR INCORPORATED BY REFERENCE HEREIN OR IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is February 15, 2023.